Fréderic Vély

PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients

Transcription Factor Bhlhe40 in Immunity and Autoimmunity

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

NK cells for cancer immunotherapy

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

NK Cell Exhaustion

Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs

Next generation immune-checkpoints for cancer therapy

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Natural killer cells and other innate lymphoid cells in cancer

Inflammation and tumor progression: signaling pathways and targeted intervention

Spatial and Temporal Mapping of Human Innate Lymphoid Cells Reveals Elements of Tissue Specificity

Harnessing innate immunity in cancer therapy

Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity

Development of therapeutic antibodies for the treatment of diseases

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Inflammation in obesity, diabetes, and related disorders

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Low Circulating Natural Killer Cell Counts are Associated With Severe Disease in Patients With Common Variable Immunodeficiency

High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice

PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma